Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Theravance Biopharma, Inc.NASDAQ: TBPH

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $4.93M (cash outflow) fell 63.7% year over year, behind the +296.4% change in trailing-twelve-month net income.

Context

  • Net income amounted to 98.5% of revenue in FY2025, up 10.9 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $148.42M (+40.2%) for the fiscal year ending Dec 2026, a slowdown from the +287.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.93M-108.1% QoQ
Last fiscal yearDec 2025
$105.9M+287.7% YoY
LTMMar 2026
$114.54M+296.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.7%-93.2%-29.5 pp
1 year+287.7%+40.2%-247.5 pp
3-year CAGR—-24.9%—
5-year CAGR-4.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
105.9M USD
Year-over-year change
+287.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +296.4% is the highest of 9, against a peer median of +25.0%.
  • Net income amounts to 104.3% of revenue for TBPH, versus a peer median of 302.7%.
TBPH Competitors
Net Income for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$442.72M USD-23.4%—676.0%
REPLReplimune Group, Inc.LTM Dec 2025$314.85M USD+37.9%+28.0%—
VALNValneva SELTM Mar 2026€146.23M EUR+81.9%-7.0%93.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$145.24M USD+14.0%+65.2%—
TYRATyra Biosciences, Inc.LTM Mar 2026$131.11M USD+36.0%+29.4%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$130.01M USD-2213.0%-29.1%302.7%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$114.54M USD+296.4%—104.3%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$109M USD+128.3%-6.7%519.3%
GERNGeron CorporationLTM Mar 2026$67.31M USD-51.6%-15.4%34.3%
Peer median (excluding TBPH) —+25.0%-6.7%302.7%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265.07M)(92.82M)(55.19M)(56.42M)105.9M
Depreciation & Amortization8.6M7.02M4.26M3.62M5.64M
Deferred Income Tax003.21M(7.57M)(11.52M)
Stock-Based Compensation62.06M39.73M25.37M21.39M18.48M
Change in Working Capital(39.55M)42.35M(8.34M)20.36M120.47M
Accounts Receivables1.8M(2.72M)(689K)(966K)(27.1M)
Inventory00000
Accounts Payables(3.53M)(1.61M)6K750K326K
Other Working Capital(37.82M)46.68M(7.66M)20.57M147.24M
Other Non-Cash Items26.1M(183.28M)3.7M7.09M(423K)
Operating Cash Flow(207.86M)(186.99M)(27M)(11.54M)238.54M
Capital Expenditures(3.41M)(572K)(2.49M)(332K)(42K)
Acquisitions (Net)00000
Purchases of Investments(158.31M)(103.15M)(134.53M)(143.04M)(248.22M)
Sales of Investments286.2M158.02M102.81M155.65M142.98M
Other Investing Activities6K1.1B1.51M00
Investing Cash Flow124.49M1.15B(32.7M)12.28M(105.28M)
Debt Repayment(10.73M)(631.6M)000
Common Stock Issued108.18M0099K786K
Common Stock Repurchased(9.06M)(132.28M)(199.55M)(3.1M)(4.03M)
Dividends Paid00000
Other Financing Activities3.47M5.08M618K508K0
Financing Cash Flow91.86M(758.81M)(198.93M)(2.5M)(3.25M)
Effect of Forex Changes00000
Net Change in Cash8.5M208.21M(258.63M)(1.75M)130.01M
Free Cash Flow(211.26M)(187.56M)(29.49M)(11.87M)238.5M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.